Does elderberry work for colds and flu? The best trial says no

Elderberry is one of the best-selling cold and flu remedies, and for a while the published evidence seemed to back it. But the studies behind that reputation are small, and when elderberry was finally put through a rigorous randomised trial against influenza, it did nothing — and a post-hoc signal even hinted at harm [s1][s2][s3]. The honest verdict is that the case is weak and the most trustworthy test came back null.

Where the optimism came from

The upbeat story rests on a handful of small trials and a meta-analysis pooling them. A 2019 review combined randomised controlled trials of black elderberry with a total of just 180 participants and reported that supplementation "substantially" reduced upper respiratory symptoms, with what the authors called a large mean effect size [s1]. The review also tried to tease apart moderators, including whether participants had been vaccinated and what was actually causing their symptoms [s1]. That headline figure is what fuelled the marketing — but 180 people across all the trials is a slender base, and the review itself was produced by a private wellness institute, a conflict worth keeping in view [s1].

The single most-cited trial studied travellers. In a 2016 study, 312 economy-class passengers flying from Australia overseas took either a standardised elderberry extract or placebo [s2]. Fewer colds occurred in the elderberry group (12 versus 17), but that difference was not statistically significant (p = 0.4) [s2]. Where the trial did reach significance was duration and severity: placebo-group participants logged 117 cold-days against 57 in the elderberry group (p = 0.02), with a higher average symptom score (583 versus 247, p = 0.05) on a standard cold-symptom scale [s2]. Suggestive — but a single small trial, in a specific stressed population, with symptoms self-recorded in a daily diary rather than confirmed in a clinic [s2].

The trial that changed the picture

Then came the test the earlier work invited. In a trial published in 2020, researchers enrolled 87 emergency-room patients aged 5 and over who had influenza confirmed by PCR and symptoms for under 48 hours, and randomly gave them elderberry extract or placebo for five days [s3]. This was the rigorous version: FDA-approved, double-blind, placebo-controlled, and powered above 0.90 to detect a two-day benefit [s3].

It found none. The average time until all symptoms were none or mild was 4.9 days on placebo versus 5.3 days on elderberry (p = 0.57), and time to complete resolution was 8.7 versus 8.6 days (p = 0.87) [s3]. Not only was there no benefit — a post-hoc analysis suggested that among patients taking elderberry alone, without the antiviral oseltamivir, outcomes were about two days worse than with placebo alone [s3]. The authors concluded there was no evidence elderberry helps the duration or severity of influenza, directly contradicting the earlier trials [s3].

How to weigh it

This is a familiar pattern in supplement research: a run of small, positive studies builds a market, and a larger, better-controlled trial then fails to reproduce the effect. Note the scale involved — US elderberry sales more than doubled to over $100 million in a single year on the strength of the softer evidence [s3]. The meta-analysis and the air-traveller trial are not worthless, but they are small, heterogeneous and, in one case, industry-linked, while the influenza trial was designed specifically to avoid those weaknesses [s1][s2][s3]. It is also worth noting what the strongest early results measured: symptom diaries and self-reported cold-days, which are easy to nudge in an unblinded or lightly blinded setting, whereas the null trial required a positive laboratory test for influenza before anyone was even enrolled [s2][s3]. When the outcome gets harder to fake, the benefit tends to disappear.

Safety is a smaller concern than efficacy: properly prepared commercial extracts were generally well tolerated in these trials, though raw or unripe elderberries are toxic and should never be eaten [s2][s3].

Bottom line

On current evidence, elderberry does not earn its billing. The promising results come from small trials and a conflicted meta-analysis; the most rigorous trial, against confirmed influenza, showed no benefit and a hint of the opposite [s1][s2][s3]. If you want remedies with a clearer (if still modest) evidence base, zinc lozenges started early have better support, and genuine influenza is better treated with the antivirals your doctor can prescribe.

This article is informational and not medical advice.

Sources

• Black elderberry (Sambucus nigra) supplementation effectively treats upper respiratory symptoms: A meta-analysis of randomized, controlled clinical trials — Complementary Therapies in Medicine, 2019-02-01
• Elderberry Supplementation Reduces Cold Duration and Symptoms in Air-Travellers: A Randomized, Double-Blind Placebo-Controlled Clinical Trial — Nutrients, 2016-03-24
• Elderberry Extract Outpatient Influenza Treatment for Emergency Room Patients Ages 5 and Above: a Randomized, Double-Blind, Placebo-Controlled Trial — Journal of General Internal Medicine, 2020-09-14